[
  {
    "ts": null,
    "headline": "Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most undervalued NASDAQ stocks to buy now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported on September 17 that its experimental medicine garetosmab has met the primary endpoint in a phase 3 trial for adults with fibrodysplasia ossificans progressiva, a rare genetic condition in which muscles, tendons, and ligaments gradually convert […]",
    "url": "https://finnhub.io/api/news?id=7e6ca79d75afd4b68bc910477e5ca1fe041e26823ad2447799134b5e1ebb128a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759172038,
      "headline": "Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease",
      "id": 136934332,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most undervalued NASDAQ stocks to buy now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported on September 17 that its experimental medicine garetosmab has met the primary endpoint in a phase 3 trial for adults with fibrodysplasia ossificans progressiva, a rare genetic condition in which muscles, tendons, and ligaments gradually convert […]",
      "url": "https://finnhub.io/api/news?id=7e6ca79d75afd4b68bc910477e5ca1fe041e26823ad2447799134b5e1ebb128a"
    }
  },
  {
    "ts": null,
    "headline": "Here’s Why Regeneron Pharmaceuticals (REGN) Fell in Q2",
    "summary": "Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. A copy of the letter can be downloaded here. Global equity markets experienced a significant shift during the quarter, moving from notable losses to reaching […]",
    "url": "https://finnhub.io/api/news?id=f00df7c30a5fa29839f27de369d61820b1138098f63236ad5d2b24c61308e8cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759156994,
      "headline": "Here’s Why Regeneron Pharmaceuticals (REGN) Fell in Q2",
      "id": 136916013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. A copy of the letter can be downloaded here. Global equity markets experienced a significant shift during the quarter, moving from notable losses to reaching […]",
      "url": "https://finnhub.io/api/news?id=f00df7c30a5fa29839f27de369d61820b1138098f63236ad5d2b24c61308e8cf"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza",
    "summary": "Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.",
    "url": "https://finnhub.io/api/news?id=ed5a18c3145bbe0101ba3c54b90391e9ea33d208dccf8e2718c619062166800c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759148880,
      "headline": "FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza",
      "id": 136916014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.",
      "url": "https://finnhub.io/api/news?id=ed5a18c3145bbe0101ba3c54b90391e9ea33d208dccf8e2718c619062166800c"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron’s Evkeeza gains FDA approval for young HoFH patients",
    "summary": "The decision to broaden the antibody’s indication was based on clinical efficacy and safety data from six children.",
    "url": "https://finnhub.io/api/news?id=9eca000020ba99c6b9d81e03574ed82af183078f54af14190e6acd644b816850",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759140137,
      "headline": "Regeneron’s Evkeeza gains FDA approval for young HoFH patients",
      "id": 136913815,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The decision to broaden the antibody’s indication was based on clinical efficacy and safety data from six children.",
      "url": "https://finnhub.io/api/news?id=9eca000020ba99c6b9d81e03574ed82af183078f54af14190e6acd644b816850"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock with Exciting Potential and 2 We Ignore",
    "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 18.3% gain.",
    "url": "https://finnhub.io/api/news?id=7f52ecc013556bdf6bcd45c01809e6edf8f068efd03700f938f6c4f5533b5830",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759120563,
      "headline": "1 Healthcare Stock with Exciting Potential and 2 We Ignore",
      "id": 136913816,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 18.3% gain.",
      "url": "https://finnhub.io/api/news?id=7f52ecc013556bdf6bcd45c01809e6edf8f068efd03700f938f6c4f5533b5830"
    }
  }
]